Polymorphic NF-Y dependent regulation of human nicotine C-oxidase (CYP2A6)

Pharmacogenetics

Volumn 14, Issue 6, 2004, Pages 369-379

  Von Richter, Oliver ^a,c   Pitarque, Marià ^a,b   Rodríguez Antona, Cristina ^a   Testa, Anna ^b   Mantovani, Roberto ^b   Oscarson, Mikael ^a,d   Ingelman Sundberg, Magnus ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF MILAN   (Italy)

^c Division of Molecular Toxicology ^*  (Germany)

^d UNIVERSITY OF BASEL   (Switzerland)

Author keywords

CYP2A6; CYP2A6* 1H; CYP2A6* 1J; Dynamic allele specific hybridization (DASH); Genetic polymorphism; NF Y; Nicotine

Indexed keywords

CYTOCHROME P450 2A6; LUCIFERASE; NICOTINE C OXIDASE; NUCLEAR FACTOR Y; NUCLEAR PROTEIN; OLIGONUCLEOTIDE; PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; BINDING AFFINITY; CELL STRAIN HEPG2; CHROMATIN; CONTROLLED STUDY; CYTOCHROME P450 2A6 GENE; CYTOCHROME P450 2A7 GENE; DNA FLANKING REGION; EXPERIMENT; GEL MOBILITY SHIFT ASSAY; GENE; GENE CONTROL; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC REGULATION; GENETIC TRANSFECTION; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPRECIPITATION; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; REGULATORY MECHANISM; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

5' FLANKING REGION; ARYL HYDROCARBON HYDROXYLASES; CARCINOMA, HEPATOCELLULAR; CCAAT-BINDING FACTOR; CHROMATIN IMMUNOPRECIPITATION; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE FREQUENCY; HAPLOTYPES; HUMANS; LIVER NEOPLASMS; LUCIFERASES; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); REGULATORY SEQUENCES, NUCLEIC ACID; TUMOR CELLS, CULTURED;

EID: 3042689406     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200406000-00006     Document Type: Article

References (54)

1. Miles JS, McLaren AW, Forrester LM, Glancey MJ, Lang MA, Wolf CR. Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J 1990; 267:365-371.
2. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990; 29:1322-1329.
3. Yun CH, Shimada T, Guengerich FP. Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol Pharmacol 1991; 40:679-685.
4. Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 2001; 29:91-95.
5. Cashman JR, Park SB, Yang ZC, Wrighton SA, Jacob P, III, Benowitz NL. Metabolism of nicotine by human liver microsomes: stereoselective formation of frans-nicotine N′-oxide. Chem Res Toxicol 1992; 5:639-646.
6. Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 1997; 282:1608-1614.
7. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, Inoue K, et al. Role of human cytochrome P4502A6 in C-oxidation of nicotine. Drug Metab Dispos 1996; 24:1212-1217.
8. Kamataki T, Nunoya K, Sakai Y, Kushida H, Fujita K. Genetic polymorphism of CYP2A6 in relation to cancer. Mutat Res 1999; 428:125-130.
9. Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, Ding X. Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanone. Cancer Res 2000; 60:5074-5079.
10. Koskela S, Hakkola J, Hukkanen J, Pelkonen O, Sorri M, Saranen A, et al. Expression of CYP2A genes in human liver and extrahepatic tissues. Biochem Pharmacol 1999; 57:1407-1413.
11. Camus AM, Geneste O, Honkakoski P, Bereziat JC, Henderson CJ, Wolf CR, et al. High variability of nitrosamine metabolism among individuals: role of cytochromes P450 2A6 and 2E1 in the dealkylation of N-nitrosodimethylamine and N-nitrosodiethylamine in mice and humans. Mol Carcinog 1993; 7:268-275.
12. Shimada T, Yamazaki H, Guengerich FP. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 1996; 26:395-403.
13. Nunoya K, Yokoi T, Kimura K, Inoue K, Kodama T, Funayama M, et al. A new deleted allele in the human cytochrome P450 2A6 (CYP2A6) gene found in individuals showing poor metabolic capacity to coumarin and (+)-cis-3,5- dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride (SM-12502). Pharmacogenetics 1998; 8:239-249.
14. Oscarson M, McLellan RA, Gullsten H, Yue QY, Lang MA, Bernal ML, et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett 1999; 448:105-110.
15. Nakajima M, Yamagishi S, Yamamoto H, Yamamoto T, Kuroiwa Y, Yokoi T. Deficient cotinine formation from nicotine is attributed to the whole deletion of the CYP2A6 gene in humans. Clin Pharmacol Ther 2000; 67:57-69.
16. Yang M, Kunugita N, Kitagawa K, Kang SH, Coles B, Kadlubar FF, et al. Individual differences in urinary cotinine levels in Japanese smokers: relation to genetic polymorphism of drug-metabolizing enzymes. Cancer Epidemiol Biomarkers Prev 2001; 10:589-593.
17. Zhang X, Ameno K, Ameno S, Kinoshita H, Kubota T, Kumihashi M, et al. Effects of whole deletion of CYP2A6 on nicotine metabolism in humans. Drug Chem Toxicol 2002; 25:203-213.
18. Kitagawa K, Kunugita N, Kitagawa M, Kawamoto T. CYP2A6*6, a novel polymorphism in cytochrome p450 2A6, has a single amino acid substitution (R128Q) that inactivates enzymatic activity. J Biol Chem 2001; 276:17830-17835.
19. Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces smoking. Nature 1998; 393:750.
20. Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers EM, et al. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Mol Pharmacol 2000; 58:747-755.
21. Loriot MA, Rebuissou S, Oscarson M, Cenee S, Miyamoto M, Ariyoshi N, et al. Genetic polymorphisms of cytochrome P450 2A6 in a case-control study on lung cancer in a French population. Pharmacogenetics 2001; 11:39-44.
22. London SJ, Idle JR, Daly AK, Coetzee GA. Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet 1999; 353:898-899.
23. Tiihonen J, Pesonen U, Kauhanen J, Koulu M, Hallikainen T, Leskinen L, et al. CYP2A6 genotype and smoking. Mol Psychiatry 2000; 5:347-348.
24. Tan W, Chen GF, Xing DY, Song CY, Kadlubar FF, Lin DX. Frequency of CYP2A6 gene deletion and its relation to risk of lung and esophageal cancer in the Chinese population. Int J Cancer 2001; 95:96-101.
25. Ariyoshi N, Miyamoto M, Umetsu Y, Kunitoh H, Dosaka-Akita H, Sawamura Y, et al. Genetic polymorphism of CYP2A6 gene and tobacco-induced lung cancer risk in male smokers. Cancer Epidemiol Biomarkers Prev 2002; 11:890-894.
26. Miyamoto M, Umetsu Y, Dosaka-Akita H, Sawamura Y, Yokota J, Kunitoh H, et al. CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem Biophys Res Commun 1999; 261:658-660.
27. Hadidi H, Zahlsen K, Idle JR, Cholerton S. A single amino acid substitution (Leu160His) in cytochrome P450 CYP2A6 causes switching from 7-hydroxylation to 3-hydroxylation of coumarin. Food Chem Toxicol 1997; 35:903-907.
28. Oscarson M, Gullsten H, Rautio A, Bernal ML, Sinues B, Dahl ML, et al. Genotyping of human cytochrome P450 2A6 (CYP2A6), a nicotine C-oxidase. FEBS Lett 1998; 438:201-205.
29. Oscarson M, McLellan RA, Gullsten H, Agundez JA, Benitez J, Rautio A, et al. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism. FEBS Lett 1999; 460:321-327.
30. Ariyoshi N, Sawamura Y, Kamataki T. A novel single nucleotide polymorphism altering stability and activity of CYP2a6. Biochem Biophys Res Commun 2001; 281:810-814.
31. Daigo S, Takahashi Y, Fujieda M, Ariyoshi N, Yamazaki H, Koizumi W, et al. A novel mutant allele of the CYP2A6 gene (CYP2A6*11) found in a cancer patient who showed poor metabolic phenotype towards tegafur. Pharmacogenetics 2002; 12:299-306.
32. Oscarson M, McLellan RA, Asp V, Ledesma M, Ruiz ML, Sinues B, et al. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity. Hum Mutat 2002; 20:275-283.
33. Rautio A, Kraul H, Kojo A, Salmela E, Pelkonen O. Interindividual variability of coumarin 7-hydroxylation in healthy volunteers. Pharmacogenetics 1992; 2:227-233.
34. Pelkonen O, Sotaniemi EA, Ahokas JT. Coumarin 7-hydroxylase activity in human liver microsomes. Properties of the enzyme and interspecies comparisons. Br J Clin Pharmacol 1985; 19:59-66.
35. Pitarque M, von Richter O, Oke B, Berkkan H, Oscarson M, Ingelman-Sundberg M. Identification of a single nucleotide polymorphism in the TATA box of the CYP2A6 gene: impairment of its promoter activity. Biochem Biophys Res Commun 2001; 284:455-460.
36. Pitarque M, von Richter O, Rodriguez-Antona C, Wang J, Oscarson M, Ingelman-Sundberg M. A nicotine C-oxidase gene (CYP2A6) polymorphism important for promoter activity. Hum Mutat 2004; 23:258-266.
37. Mantovani R. A survey of 178 NF-Y binding CCAAT boxes. Nucleic Acids Res 1998; 26:1135-1143.
38. Westlind A, Malmebo S, Johansson I, Otter C, Andersson TB, Ingelman-Sundberg M, et al. Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43. Biochem Biophys Res Commun 2001; 281:1349-1355.
39. Dignam JD, Lebovitz RM, Roeder RG. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983; 11:1475-1489.
40. Gronostajski RM. Roles of the NFI/CTF gene family in transcription and development. Gene 2000; 249:31-45.
41. Boyd KE, Wells J, Gutman J, Bartley SM, Farnham PJ. c-Myc target gene specificity is determined by a post-DNAbinding mechanism. Proc Natl Acad Sci U S A 1998; 95:13887-13892.
42. Bolognese F, Wasner M, Dohna CL, Gurtner A, Ronchi A, Muller H, et al. The cyclin B2 promoter depends on NF-Y, a trimer whose CCAAT-binding activity is cell-cycle regulated. Oncogene 1999; 18:1845-1853.
43. Mantovani R, Li XY, Pessara U, Hooft vH, Benoist C, Mathis D. Dominant negative analogs of NF-YA. J Biol Chem 1994; 269:20340-20346.
44. Howell WM, Jobs M, Gyllensten U, Brookes AJ. Dynamic allele-specific hybridization. A new method for scoring single nucleotide polymorphisms. Nat Biotechnol 1999; 17:87-88.
45. Prince JA, Feuk L, Howell WM, Jobs M, Emahazion T, Biennow K, et al. Robust and accurate single nucleotide polymorphism genotyping by dynamic allele-specific hybridization (DASH): design criteria and assay validation. Genome Res 2001; 11:152-162.
46. Zhang P, Sheng H, Morabia A, Gilliam TC. Optimal step length EM algorithm (OSLEM) for the estimation of haplotype frequency and its application in lipoprotein lipase genotyping. BMC Bioinformatics 2003; 4:3.
47. Wingender E, Dietze P, Karas H, Knuppel R. TRANSFAC: a database on transcription factors and their DNA binding sites. Nucleic Acids Res 1996; 24:238-241.
48. Bucher P, Trifonov EN. Compilation and analysis of eukaryotic POL II promoter sequences. Nucleic Acids Res 1986; 14:10009-10026.
49. Dorn A, Bollekens J, Staub A, Benoist C, Mathis D. A multiplicity of CCAAT box-binding proteins. Cell 1987; 50:863-872.
50. Iwano S, Saito T, Takahashi Y, Fujita K, Kamataki T. Cooperative regulation of CYP3A5 gene transcription by NF-Y and Sp family members. Biochem Biophys Res Commun 2001; 286:55-60.
51. Boucher PD, Piechocki MP, Hines RN. Partial characterization of the human CYP1A1 negatively acting transcription factor and mutational analysis of its cognate DNA recognition sequence. Mol Cell Biol 1995; 15:5144-5151.
52. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A 2000; 97:10483-10488.
53. Kiyotani K, Yamazaki H, Fujieda M, Iwano S, Matsumura K, Satarug S, et al. Decreased coumarin 7-hydroxylase activities and CYP2A6 expression levels in humans caused by genetic polymorphism in CYP2A6 promoter region (CYP2A6*9). Pharmacogenetics 2003; 13:689-695.
54. Yoshida R, Nakajima M, Nishimura K, Tokudome S, Kwon JT, Yokoi T. Effects of polymorphism in promoter region of human CYP2A6 gene (CYP2A6*9) on expression level of messenger ribonucleic acid and enzymatic activity in vivo and in vitro. Clin Pharmacol Ther 2003; 74:69-76.